Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 23/2/2018
SIETES contiene 92199 citas

 
 
 1 a 20 de 513 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
2. Cita con resumen
Anónimo. GSK cuts back operations in Africa. DIA Daily 2018:1. [Ref.ID 102445]
4. Cita con resumen
Anónimo. Litigation is new tactic in opioid crisis. DIA Daily 2017:1. [Ref.ID 101500]
5. Cita con resumen
Anónimo. eva to buy Allergan’s Anda distribution business, pending approval. DIA Daily 2016:1. [Ref.ID 100565]
6.Tiene citas relacionadas Cita con resumen
Kuller LH. Do proton pump inhibitors increase the risk of dementia?. JAMA Neurology 2016;73:379-81. [Ref.ID 100322]
7. Cita con resumen
Anónimo. Drugs past their expiration date. JAMA 2016;315:510-1. [Ref.ID 100021]
8. Cita con resumen
Hampton T. New drug delivery technologies may advance personalized cancer therapy. JAMA 2015;313:2114. [Ref.ID 99118]
9. Cita con resumen
Anónimo. Drug shortages rose 74% over last five years in US. DIA Daily 2015:1 de junio. [Ref.ID 99109]
10. Cita con resumen
Anónimo. Codeine for cough and cold: restricted use in children. Drug Safety Update 2015;8:2. [Ref.ID 99022]
11. Cita con resumen
Casassus B. Europe urged to take action on drug shortages. Lancet 2015;385:1279-80. [Ref.ID 99016]
12. Cita con resumen
Anónimo. Suvorexant (Belsomra) for insomnia. Med Lett Drugs Ther 2015;57:29-31. [Ref.ID 98878]
13. Cita con resumen
Li DQ, Kim R, McArthur E, Fleet JL, Bailey DG, Juurlink D, Shariff SZ, Gomes T, Mamdani M, Gandhi S, Dixon S, Garg AX. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. Can Med Assoc J 2015;187:174-80. [Ref.ID 98758]
15. Cita con resumen
Anónimo. Colchicine: encore des morts. Prescrire 2014;34:266. [Ref.ID 97438]
16. Cita con resumen
Anónimo. Sofosbuvir (Sovaldi) for chronic hepatitis C. Med Lett Drugs Ther 2014;56:5-6. [Ref.ID 97219]
17. Cita con resumen
Anónimo. Simeprevir (Olysio) for chronic hepatitis C. Med Lett Drugs Ther 2014;56:1-2. [Ref.ID 97179]
18. Cita con resumen
Thompson AJ, Giovannoni G. Removal of alemtuzumab for patients with aggressive MS. BMJ 2013;346:10. [Ref.ID 94828]
19.Tiene citas relacionadas
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DAS, for the CARE-MS II Investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39. [Ref.ID 94117]
20.Tiene citas relacionadas
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DAS, for the CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1818-29. [Ref.ID 94116]
Seleccionar todas
 
 1 a 20 de 513 siguiente >>